Fabrizio Rinaldi

Fabrizio Rinaldi

Auto-generated profile, based on publicly available information

Fabrizio Rinaldi

Department of Neurology, Hospital of Merano (SABES-ASDAA), Merano, Italy

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Epilepsy & Behavior
Verified
Journal Article
Closed access
FDFedele Dono
Fedele Dono
BNBruna Nucera
Bruna Nucera
JLJacopo Lanzone
Jacopo Lanzone
GEGiacomo Evangelista
Giacomo Evangelista
FRFabrizio Rinaldi
Fabrizio Rinaldi
Francesco BrigoFrancesco Brigo
Francesco Brigo

5 January 2014 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
EPElisa Pari
Elisa Pari
FRFabrizio Rinaldi
Fabrizio Rinaldi
EPEnrico Premi
Enrico Premi
MCMaria Codella
Maria Codella
RRRenata Rao
Renata Rao
APAlessandro Padovani
Alessandro Padovani

5 May 2023 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
BNB. Nucera
B. Nucera
FRF. Rinaldi
F. Rinaldi
FDF. Dono
F. Dono
JLJ. Lanzone
J. Lanzone
GEG. Evangelista
G. Evangelista
Francesco BrigoFrancesco Brigo
Francesco Brigo

15 September 2023 in Epilepsia Open
Verified
Journal Article
Open access
FDFedele Dono
Fedele Dono
SCStefano Consoli
Stefano Consoli
MTMaria Tappatà
Maria Tappatà
GEGiacomo Evangelista
Giacomo Evangelista
MRMirella Russo
Mirella Russo
RMRoberto Michelucci
Roberto Michelucci
Several reports have described the autoimmune encephalitis' (AE) possible onset during pregnancy. In this systematic review, we summarize the available data on the diagnostic and therapeutic approach to AE during pregnancy, highlighting the associated maternal and fetal clinical outcomes. A systematic search of the literature was performed. The following databases were used: PubMed, Google Scholar, EMBASE, and CrossRef. The revision was registered on the PROSPERO platform (CRD42022336357). Forty‐nine patients were included. AE onset was mainly observed during the first and the second trimester of pregnancy with psychiatric manifestations and seizures as main onset symptoms. CSF analysis showed AE‐specific autoantibody positivity in 33 patients (anti‐NMDA receptor as the most frequent). EEG generally showed normal findings. MRI revealed pathological findings in less than half of patients. Tumor screening was positive in 14 cases. First‐line immunotherapy (single or combined) was generally employed while second line was administered in a minority of patients. Levetiracetam was the most used antiseizure medication. Cesarean section was performed in 18 women. Most of the women had an excellent early outcome after delivery but 22 showed persistent neurological deficits in long‐term follow‐up. Fetal outcome was positive in 33 cases, whereas 12 cases of fetal death were reported. A logistic regression showed that no variable significantly influenced the odds of good/bad maternal and fetal clinical outcome. Diagnosis and treatment of AE during pregnancy is challenging. The rate of miscarriage in women with AE seems to be higher than the general population. In addition, mothers may show long‐term neurological deficits.

12 February 2016 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
FRFabrizio Rinaldi
Fabrizio Rinaldi
SNStefano Nembrini
Stefano Nembrini
CCCarlo Concoreggi
Carlo Concoreggi
MMMauro Magoni
Mauro Magoni
APAlessandro Padovani
Alessandro Padovani

1 October 2018 in International Journal of Epilepsy
Verified
Journal Article
Open access
PDF file
FRFabrizio Rinaldi
Fabrizio Rinaldi
GMGiovanni De Maria
Giovanni De Maria
Background The main purpose of this study is to assess efficacy and tolerability of perampanel (PER), a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor antagonist, as an add-on treatment in adult patients with refractory focal-onset seizures. Patients and Methods A prospective, open label, observational study was conducted in patients with refractory focal-onset seizures treated with PER at our Epilepsy Unit, from May 2015 to February 2016. Patients were followed up for 1 year. Frequency of seizure and tolerability was assessed every 3 months. Patients were under a polytherapy, and the mean number of concomitant antiepileptic drugs (AEDs) at PER initiation was 2.9. Results We consecutively enrolled 52 patients (M/F = 18/34). Three were lost on follow-up. Mean age was 38.7 years, with a mean duration of disease of 28.1 years. After 1 year of treatment, 57.14% reported a 50% or greater reduction in seizure frequency; five (10.21%) were seizure free. Six (12.25%) patients reported a reduction lower than 50%. Mean dosage of PER was 7.57 mg. Thirty-one patients were taking enzyme-inducing AEDs (carbamazepine, oxcarbazepine, phenytoin). In this subgroup, the responder rate was 45.2%. Twenty-one patients reported side-effects, most frequently somnolence (11), vertigo/ataxia (6), and aggressiveness (5). Eleven (22.4%) patients reduced or discontinued at least one concomitant AED, while the electroencephalography improved in four (8.16%). Sixteen (32.65%) patients withdrew PER, after a mean duration of 163 days, the mean dosage being 6.4 mg (range 4–12). Conclusions Adjunctive PER can achieve clinically meaningful improvement, or even seizure freedom, in almost two-thirds of patients suffering from refractory focal-onset epilepsies. It seems similarly safe and well-tolerated. Enzyme-inducing AEDs may limit the efficacy of PER.